Press release
Global Parents for Eczema Research (GPER) Announces Childhood Eczema Prevention Grant
Image of infant with Atopic Dermatitis (AD or "eczema")
"We are dedicated to advancing knowledge and strategies that can help prevent childhood eczema and halt the rise in suffering that parallels the increasing prevalence," said Korey Capozza, Executive Director of GPER. "Through our 2024 grantmaking program, we aim to support innovative approaches to primary and secondary prevention of AD."
The Childhood Eczema Prevention Grant prioritizes two areas that have shown promise in preventing AD and other allergic conditions: gut microbiome modulation during prenatal and postnatal periods and early topical therapy in infancy. The 2024 grants will also support patient-centered research questions.
"We are particularly interested in research proposals that not only contribute to scientific knowledge but also resonate with the concerns and interests of patients and families affected by eczema," said Capozza.
GPER will award up to three grants, each up to USD$25,000, for the 2024 funding cycle.
Applications for the Childhood Eczema Prevention Grant are now open. Interested parties should submit a one-page Letter of Intent by April 30th, 2024 . For more information and to apply, visit www.gper.org/grants.
Korey Capozza, MPH
Executive Director, Global Parents for Eczema Research
1117 State Street, Santa Barbara, CA 93101
korey@gper.org
805-232-4479
About Global Parents for Eczema Research (GPER): GPER is a global, grassroots, non-profit organization whose mission is to end the suffering of children with eczema by advancing research and empowering families. For more information: www.gper.org.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global Parents for Eczema Research (GPER) Announces Childhood Eczema Prevention Grant here
News-ID: 3426067 • Views: …
More Releases from Global Parents for Eczema Research
Global Parents for Eczema Research (GPER) Awards Two Grants to Advance Childhood …
Santa Barbara, CA, October 15, 2024 - Global Parents for Eczema Research (GPER), a nonprofit organization dedicated to improving the lives of children suffering from eczema (atopic dermatitis, AD), announced the funding of two groundbreaking research projects as part of its 2024 Childhood Eczema Prevention Grant program. These grants will each provide up to $25,000 to support clinical research focused on preventing eczema in children.
Eczema affects up to 20% of…
"BIG IDEAS FOR ECZEMA RESEARCH CHALLENGE" WINNERS ANNOUNCED
Three parents of children with eczema win top prizes for their innovative ideas for research based on their "lived experience".
Santa Barbara, CA, May 23, 2024 - Global Parents for Eczema Research is pleased to announce the winners of its annual "Big Ideas for Eczema Challenge", a global contest that rewards patients and their caregivers for their novel ideas for eczema research. The goal is to improve the understanding of eczema,…
More Releases for GPER
Obesity Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment …
DelveInsight's, "Obesity - Pipeline Insight, 2025" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Obesity companies are Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma,…
Obesity Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment …
Obesity Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | 180 Life Sciences, 9 meters, Aardvark Therapeutics, Adocia, Agentix, AgeX Therapeutics, Altimmune, Amgen, Antag Therapeutics, Aphaia Pharma, Aptorum Group, AstraZeneca, Betagenon AB, BioRestorative, Boehringer Ingelheim, Braasch Biotech, Bristol-Myers Squibb, Bukwang Pharmaceutical, Caliway Biopharmaceutics Co Ltd, Can Fite Biopharma, Carmot Therapeutics, Inc., Cellivery Therapeutics Inc, CinFina, CinFina Pharma, Clayton Biotech, Click Therapeutics, CohBar, Corbus…
Global Parents for Eczema Research (GPER) Awards Two Grants to Advance Childhood …
Santa Barbara, CA, October 15, 2024 - Global Parents for Eczema Research (GPER), a nonprofit organization dedicated to improving the lives of children suffering from eczema (atopic dermatitis, AD), announced the funding of two groundbreaking research projects as part of its 2024 Childhood Eczema Prevention Grant program. These grants will each provide up to $25,000 to support clinical research focused on preventing eczema in children.
Eczema affects up to 20% of…
"BIG IDEAS FOR ECZEMA RESEARCH CHALLENGE" WINNERS ANNOUNCED
Three parents of children with eczema win top prizes for their innovative ideas for research based on their "lived experience".
Santa Barbara, CA, May 23, 2024 - Global Parents for Eczema Research is pleased to announce the winners of its annual "Big Ideas for Eczema Challenge", a global contest that rewards patients and their caregivers for their novel ideas for eczema research. The goal is to improve the understanding of eczema,…
Obesity Pipeline, FDA Approvals, Clinical Trials Developments and Companies | Aa …
DelveInsight's, "Obesity Pipeline Insight 2023" report provides comprehensive insights about 100+ companies and 130+ pipeline drugs in the Obesity pipeline landscape. It covers the Obesity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obesity pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space.
Key Takeaways from the Obesity Pipeline Report
• DelveInsight's…
Obesity Pipeline and Clinical Trials Pipeline Analysis 2023 (Updated): 100+ Comp …
(Albany, United States) As per DelveInsight's assessment, globally, the Obesity Pipeline constitutes 100+ key companies continuously working towards developing 130+ Obesity treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Obesity Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Sepsis clinical trials studies, Obesity NDA approvals (if any), and…
